PMPRB report examines availability and pricing of new medicines
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.
News results
Showing 1 - 10 of 71 results
Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.
PMPRB releases What We Learned Report from recent Policy Roundtable
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) today published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines.
PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures
| Patented Medicine Prices Review Board Canada | news releases
PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.
PMPRB announces next steps in Guidelines consultation process
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable.
PMPRB report reveals most new medicines come to market with high treatment costs
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.
New report examines new drugs in the pipeline that may significantly impact future drug spending in Canada
| Patented Medicine Prices Review Board Canada | news releases
Oncology continued to dominate the therapeutic mix of the drug pipeline in 2022.
PMPRB consults on new proposed Interim Guidance
| Patented Medicine Prices Review Board Canada | news releases
PMPRB consults on new proposed Interim Guidance
Spending on antidiabetic drugs in Canada outpaced overall drug market
| Patented Medicine Prices Review Board Canada | news releases
Canadian prices for top-selling antidiabetic drugs were higher than those in the PMPRB’s comparator countries from 2012 to 2021.
Patented Medicine Prices Review Board seeks applicants for vacant Board positions
| Patented Medicine Prices Review Board Canada | news releases
The Government of Canada is seeking applicants for the Vice Chairperson position and two Board Member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-based Governor in Council selection processes.
Page details
- Date modified: